Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28617611 | 0.79 | CDC7 (0.53) | GAAHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL695288 | 0.78 | ROCK1 (0.45) | CDC7CDK2ROCK1 | |
| SCHEMBL694240 | 0.77 | POLB (0.41) | CDC7CDK2ROCK1MAPTRAB9A | |
| SCHEMBL694874 | 0.75 | ROCK1 (0.39) | ROCK1MAPT | |
| SCHEMBL695323 | 0.74 | ROCK1 (0.47) | CDC7CDK2ROCK1MAPTSMN1; SMN2 | |
| SCHEMBL4265823 | 0.73 | ALDH1A1 (0.41) | RAB9AL3MBTL1KDM4E | |
| SCHEMBL694549 | 0.73 | DGAT1 (0.40) | MAPT | |
| SCHEMBL16720395 | 0.72 | ALDH1A1 (0.38) | MAPTSMN1; SMN2KDM4E | |
| SCHEMBL694759 | 0.71 | RPS6KA5 (0.47) | CDC7CDK2ROCK1MAPT | |
| SCHEMBL16720318 | 0.71 | BIRC5 (0.39) | ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE KA RECHERCHE MÉDICALE (FR) | 2018-09-18 | — | — | US | claimed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | claimed |
| US-8691805-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-04-08 | — | — | US | claimed |
| EP-2421825-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-01 | — | — | EP | claimed |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | claimed |
| US-8455476-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-06-04 | — | — | US | claimed |
| EP-2421825-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-20190216804-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-07-18 | — | — | US | disclosed |
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE KA RECHERCHE MÉDICALE (FR) | 2018-09-18 | — | — | US | disclosed |
| US-20170239242-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | UNIVERSITÉ PARIS CITÉ (FR) | 2017-08-24 | — | — | US | disclosed |
| EP-3197450-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046130-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-03-31 | — | — | WO | disclosed |
| EP-2421825-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-01 | — | — | EP | disclosed |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | disclosed |
| US-8455476-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-06-04 | — | — | US | disclosed |
| EP-2421825-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | LIPA, MGLL, PNLIP | GAA 33/4885HTR3E 1882/4885HTR3B 1708/4885 |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | GAA 22/4885HTR3E 2201/4885HTR3B 2451/4885 |
| US-20170239242-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | LIPA, MGLL, PNLIP | GAA 33/4885HTR3E 1882/4885HTR3B 1708/4885 |
| US-20190216804-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | MGLL, LIPA, PNLIP | GAA 35/4885HTR3E 1843/4885HTR3B 1679/4885 |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | GAA 22/4885HTR3E 2201/4885HTR3B 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.